finance.yahoo.com Regulatory and legal
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
Bavarian Nordic A/S MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN's position in supporting global public health preparedness COPENHAGEN, Denmark, August 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the …